Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Fanouriakis, Antonis; Adamichou, Christina; Koutsoviti, Sofia; Panopoulos, Stylianos; Staveri, Chrysanthi; Klagou, Anastasia; Tsalapaki, Christina; Pantazi, Lamprini; Konsta, Styliani; Mavragani, Clio; Dimopoulou, Despoina; Ntali, Styliani; Katsikas, Georgios; Boki, Kyriaki; Vassilopoulos, Dimitrios; Konstantopoulou, Pinelopi; Liossis, Stamatis-Nick; Elezoglou, Antonia; Tektonidou, Maria; Sidiropoulos, Prodromos; ERDEN, ABDULSAMET; Sfikakis, Petros; Bertsias, George; Boumpas, Dimitrios

doi:10.1016/j.semarthrit.2018.02.014

Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Fanouriakis A., Adamichou C., Koutsoviti S., Panopoulos S., Staveri C., Klagou A., ...Daha Fazla

SEMINARS IN ARTHRITIS AND RHEUMATISM, cilt.48, sa.3, ss.467-474, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Derleme
Cilt numarası: 48 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.semarthrit.2018.02.014
Dergi Adı: SEMINARS IN ARTHRITIS AND RHEUMATISM
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.467-474
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.